ANGELI

ELENCO DELLE PUBBLICAZIONI

Febbraio 2015

PUBBLICAZIONI SU RIV ISTE « INDEXED »

(TOTAL IMPACT FACTOR = 929.066) 1) Renal water and sodium handling in compensated live r cirrhosis: mechanism of the impaired natriuresis after salin e loading. Caregaro L., Lauro S., Angeli P. , Merkel C., Gatta A. Eur. J. Clin. Invest. 1985 ; 15 : 360-364. IF= 2.834 2) Tubular handling of sodium and phosphate in non-asc itic liver cirrhosis. Caregaro L., Angeli P. , Merlo A., Rondana M., Merkel C., Gatta A. Scand. J. Clin. Lab. Invest. 1987 ; 47 : 247-251.

IF= 2.009

3) Glomerular filtration rate is increased in man by t he infusion both of DL-3-Hydroxybutyric acid and sodium DL-3-Hydroxyb utyrate infusion. Fioretto P., Trevisa R., Velussi M., Cernigoi A., De Riva C., Bressan M., Doria A, Pauletto N., Angeli P. , De Dona C., Nosadini R. J. Clin. Endocrinol. Metab. 1987 ; 65 : 331-338. IF=6.310 4) Nadolol for prevention of variceal rebleeding in c irrhosis: a controlled clinical trial. Gatta A., Merkel C., Sacerdoti D., Bolognesi ., Zuin R., Angeli P. , Ruol A. Digestion 1987 ; 37 : 22-28.

IF=2.032

5) Long-term effects of beta-agrenergic blockade with nadolol on hepatic and renal haemodynamics and function in c irrhotics. Gatta A., Bolognesi M., Merkel C., Finucci GF., Angeli P., Sacerdoti D., Ruol A. Clin. Physiol. 1987 ; 7 : 377-387. IF= 1.380

6) Type I insulin- dependent diabetic patients show an impaired renal

hemodynamic response to protein intake. Fioretto P, Trevisan R, Giorato C, De Riva C, Doria A, Valerio A, Semplicini A, Angeli P , Cipollina MR, Nosadini R. J Diabet Complications. 1988 Jan-Mar;2(1):27-9

IF= 1.925

7) Hemodynamic changes of systemic, hepatic, and spl enic circulation following triglycyl-lysin-vasopressin administrat ion in alcoholic cirrhosis. Merkel C., Gatta A., Bolognesi M., Finucci GF., Battaglia G., Angeli P. , Zuin R. Dig. Dis.Sci. 1988 ; 33 : 1103-1108.

IF=2.550

8) Detection of the early steps of cadmium nephropat y, comparison of light and electron-microscopical patterns with ur inary enzymes: an experimental study. Gatta A., Bazzerla G., Amodio P., Menon F., Angeli P. , Schiaffino E., Schmid C. Nephron 1988 ; 51 ; 20-24. IF=1.765 9) Liver metabolism of indocyanine green and aminopyri ne in liver

cirrhosis: relations with functioning liver cell ma ss]. Bolognesi M, Merkel C, Angeli P , Caregaro L, Gatta A. Minerva Med. 1988 Dec;79(12):1035-41. Italian. I.F=1.202

10) Effects of iloprost, a prostacyclin analog deriva tive, on renal plasma

flow, renal function and on renin-angiotensin-aldo sterone system in humans .

Angeli P., Gatta A., Caregaro L., Menon F., Sacerdoti D., Merkel C., Visonà A., Lusiani L., Pagnan A. Clin. Pharmacol. Ther. 1988 : 44 ; 211-216. IF=7.390 11) The calcium-channel blocker, verapamil, does not improve portal

pressure in patients with alcoholic cirrhosis. Merkel C., Gatta A., Bolognesi M., Padrini R., Finucci GF., Angeli P. , Ruol A. Br. J. Clin. Pharmacol. 1988 ; 26 : 273-277. IF=3.688

12) Impaired renal water excretion in liver cirrhosis: the role of the

reduced distal delivery of sodium. Gatta A., Caregaro L., Angeli P. , Merkel C., Menon F., Rondana M., Ruol A. Scand. J. Gastroenterol. 1988 ; 23 : 523-528.

IF=2.329 13) Indocyanine green intrinsic hepatic clearance as a prognostic index

of survival in patients with cirrhosis. Merkel C., Bolognesi M., Finucci GF., Angeli P. , Caregaro L., Rondana M., Gatta A. J. Hepatol. 1989 ; 9 : 16-22. IF=10.401 14) Prognostic indicators of survival in patients wit h cirrhosis and

esophageal varices, without previous bleeding. Merkel C., Bolognesi M., Angeli P. , Noventa F., Caregaro L., Sacerdoti D., Gatta A. Am. J. Gastroenterol. 1989 ; 84 : 717-722.

IF=9.213

15) Tubular Na+

handling in type I insulin-dependent diabetics dur ing saline and ketone body infusion.

Semplicini A., Angeli P. , Nosadini R., Trevisan R., Fioretto P., Doria A., Rigon E., Sama B. Diabetes Res. 1889 ; 11 : 67-72. IF=3.536 16) Clinical and hemodynamic effects of iloprost in p atients suffering

from peripheral vascular disease. Visonà A., Lusiani L., Gava R., Scaldalai E., Angeli P. , Caregaro L., Miraglia G., Gatta A., Pagnan A. Curr. Ther. Res. 1989 ; 45 : 794-803.

IF=0.333 17) Tubular site of renal sodium retention in ascitic liver cirrhosis

evaluated by lithium clearance. Angeli P. , Gatta A., Caregaro L., Menon F., Sacerdoti D., Merkel C., Rondana M., De Toni R., Ruol A. Eur. J. Clin. Invest. 1990 ; 20 : 111-117.

IF=2.834

18) Plasma carnitine levels in liver cirrhosis: relatio nship with nutritional status

and liver damage. Amodio P, Angeli P , Merkel C, Menon F, Gatta A. J Clin Chem Clin Biochem. 1990 Sep;28(9):619-26.

I.F=1.490 19) Lack of effect of verapamil and isosorbide dinitrat e on the hepatic clearance of indocyanine green in cirrhosis. Merkel C., Bolognesi M., Angeli P., Finucci GF., Amodio P., Bellon S., Gatta A. Br. J. Clin. Pharmacol. 1990 ; 30 : 221-227.

IF=3.688

20) ANP and PRA system response to phlebotomy (letter) . Casiglia E., Angeli P., De Toni R., Gatta A., Pessina AC. Am. Heart. J. 1990 ; 120 (6 ; Pt 1) : 1485. IF=4.555 21) Pharmacokinetics of iloprost in patients with hepa tic dysfunction. Hildebrand M., Krause W., Angeli P ., Koziol T., Gatta A., Merkel C., Bolognesi M. Int. J. Clin. Pharmacol. Ther. Toxicol. 1990 ; 28 : 430-434.

IF=1.351

22) A pathophysiological interpretation of unresponsive ness to spironolactone in a stepped-care approach to the diuretic treatment of ascites in nonazotemic cirrrhotic patients. Gatta A., Angeli P., Caregaro L., Menon F., Sacerdoti D., Merkel C.

Hepatology 1991 ; 14 : 231-236. IF=

11.190 23) Prognostic value of galactose elimination capacit y, aminopyrine breath test, and ICG clearance in patients with c irrhosis. Comparison with the Pugh score. Merkel C., Gatta A., Zoli M., Bolognesi M., Angeli P ., Iervese T., Marchesini G., Ruol A.. Dig. Dis. Sci. 1991 ; 36 : 1197-1203.

IF=2.550 24) Hypophosphatemia and renal tubular dysfuncton in alcoholics: are they related to liver function impairment ? Angeli P. , Gatta A., Caregaro L., Luisetto G., Menon F., Merkel C., Bolognesi M., Ruol A. Gastroenterology 1991 ; 100 : 502-512. IF=13.926 25) Comparison of sublingual captopril and nifedipine i n immediate treatment of hypertensive emergencies. A randomiz ed, single-blind clinical trial. Angeli P ., Chiesa M., Caregaro L., Merkel C., Sacerdoti D., Rondana M., Gatta A. Arch. Intern. Med. 1991 ; 151 : 678-682. IF=13.246 26) Increased renal production of cytochrome P450-dep endent metabolites

of arachidonic acid in cyclosporine-induced nephrot oxicity. Sacerdoti D, Borsato M, Rigotti P, Amodio P, Angeli P , Ferraresso M, Plebani M, Gatta A.

Adv Prostaglandin Thromboxane Leukot Res. 1991;21B:689-92. No abstract available. 27) Effects of defibrotide on renal function and urin ary prostanoid excretion in ciclosporin-treated rats. Rigotti P., Amodio P., Sacerdoti D., Ferraresso M., Borsato M., Morpurgo E., Menon F., Angeli P. Nephron 1991 ; 59 : 477-481.

IF=1.765

28) Prognostic usefulness of hepatic vein catheteriza tion in patients with cirrhosis and esophageal varices. Merkel C., Bolognesi M., Bellon S., Zuin R., Noventa F., Finucci GF., Sacerdoti D., Angeli P ., Gatta A. Gastroenterology 1992 ; 102 : 973-979. IF=13.926 29) Alcohol and renal phosphate excretion. Angeli P ., Gatta A. Gastroenterology 1992 ; 100 : 379 (letter).

IF=13.926

30) Effects of amiloride on renal lithium handling in nonazotemic ascitic cirrhotic patients with avid sodium retention. Angeli P., De Bei E., Dalla Pria M., Caregaro L., Ceolotto G., Albino G., Gatta A.

Hepatology 1992 ; 15 : 651-654. IF=

11.190 31) Aminopyrine breath test in the prognostic evaluat ion of patients with cirrhosis. Merkel C., Bolognesi M., Bellon S., Bianco S., Honisch B., Lampe H., Angeli P., Gatta A. Gut 1992 ; 33 : 836-842. IF=13.319 32) Cardiac involvement in liver cirrhosis .

Gatta A, Merkel C, Sacerdoti D, Angeli P. Ann Ital Med Int. 1993 Oct-Dec;8(4):244-7. Review.

I.F=16.104 33) Variability of atrial natriuretic peptide plasma l evels in ascitic chirrotics; pathophysiological and clinical impl ications. Angeli P ., Caregaro L., Menon F., Sacerdoti D., De Toni R., Merkel C., Gatta A.. Hepatology 1992 ; 16 : 1389-1394. IF=11.190 34) Renal excretion and diuretic effect of furosemide i n patients with ascitic liver cirrhosis . Padrini R., Angeli P ., Piovan L., Caregaro L., Gatta A., Ferrari M. Pharmacol. Res. 1992 ; 25 (suppl. 2) : 206-207.

IF=3.976

35) Renal vasoconstriction in cirrhosis evaluated by d uplex Doppler ultrasonography. Sacerdoti D., Bolognesi M., Merkel C., Angeli P ., Gatta A.. Hepatology 1993 ; 17 : 219-224.

IF=11.190

36) Randomized clinical study of the efficacy of amilo ride and potassium canrenoate in nonazotemic cirrhotic patients wit h ascites.

Angeli P ., Dalla Pria M., De Bei E., Albino G., Caregaro L., Merkel C., CeolottoG., Gatta A. Hepatology 1994 ; 19 : 72-79. IF=11.190

37) Renal vasoconstriction in cirrhosis. Sacerdoti D., Bolognesi M., Merkel C., Angeli P ., Gatta A. Hepatology 1994 ; 20 : 539-541 (letter). IF=11.190

38) Limitations of serum creatinine level and creatini ne clearance as filtration markers in cirrhosis. Caregaro L., Menon F., Angeli P ., Amodio P., Merkel C., Bortoluzzi A., Alberino F., Gatta A.. Arch. Intern. Med. 1994 ; 154 : 201-205. IF=13.246 39) Clinical significance of the evaluation of hepatic reticuloendothelial removal capacity in patients with cirrhosis. Bolognesi M., Merkel C., Bianco S., Angeli P ., Sacerdoti D., Amodio P., Gatta A. Hepatology 1994 ; 19 : 628-634. IF=11.190 40) HS-142-1, a potent antagonist of natriuretic pept ides in vitro and in vivo.

Zhang PL, Jimenez W., Mackenzie HS., Guo J., Troy JL., Ros J., Angeli P., Arroyo V., Brenner BM. J. Am. Soc. Nephrol. 1994 : 5 : 1099-1105. IF=9.466 41) Renal effects of natriuretic peptide receptor blo ckade in cirrhotic rats with ascites. Angeli P., Jimenez W., Arroyo V., Mackenzie HS., Zhang PL., Claria J., Rivera F., Brenner BM., Rodes J. Hepatology 1994 ; 20 : 948-954. IF=11.190 42) Increased nitric oxide-dependent vasorelaxation i n aortic rings of cirrhotic rats with ascites. Claria J., Jimenez W., Ros J., Rigol M., Angeli P ., Arroyo V., Rivera F., Rodes J. Hepatology 1994 ; 20 : 1615-1621.

IF=11.190 43) Role of nitric oxide and prostacyclin in the contr ol of renal perfusion in experimental cirrhosis.

Ros J., Claria J., Jimenez W., Bosch-Marce M., Angeli P ., Arroyo V., Rivera F., Rodes J. Hepatology 1995 ; 22 : 808-813.

IF=11.190 44) Long-term effect of nadolol or nadolol plus isosor bide-5-mononitrate on renal function and ascites formation in patien ts with cirrhosis. Merkel ., Gatta A., Donada C., Enzo E., Marin R., Amodio P., Torboli P., Angeli P ., Cavallarin G., Sebastianelli G., Hepatology 1995 ; 22 : 808-813.

IF=11.190 45) Treatment of patients with cirrhosis and refracto ry ascites using LeVeen shunt with titanium tip: comparison with t herapeutic paracentesis. Ginès A., Planas R., Angeli P ., Guarner C., Salerno F., Ginès A., Salo J., Rodriguez N., Domènech E., Soriano G., Anibarro L., Gassull MA., Gatta A., Arroyo V., Rodés J. Hepatology 1995 ; 22 : 124-131.

IF=11.190 46) Hepatic arterial resistance in cirrhosis with and without portal vein thrombosis: relationships with portal hemodynamic s. Sacerdoti D., Merkel C., Bolognesi M., Amodio P., Angeli P ., Gatta A. Gastroenterology 1995 ; 108 : 1152-1158.

IF=13.926 47) Acquaretic effect of the kappa-opioid agonist RU 51599 in cirrhotic rats with ascites and water retention. Bosch-Marce M., Jimenez W., Angeli P ., Leivas A., Claria J., Graziotto A., Arroyo V., Rivera F., Rodes J. Gastroenterology 1995 : 109 : 217-223.

IF=13.926 48) Malnutrition in alcohol and virus-related cirrho sis. Caregaro L., Alberino F., Amodio P., Merkel C., Bolognesi M., Angeli P., Gatta A. Am. J. Clin. Nutr. 1996 ; 63 :602-609.

IF=6.918 49) Cirrhosis and muscle cramps: evidence of a causal relationship. Angeli P ., Albino G., Carraro P., Dalla Pria M., Merkel C., Caregaro L., De Bei E., Bortoluzzi A., Plebani M., Gatta A.. Hepatology 1996 ; 23 : 264-273.

IF=11.190 50) Urinary excretion of urodilatin in patients with cirrhosis.

Saló J, Jiménez W, Kuhn M, Ginès A, Ginès P, Fernández-Esparrach G, Angeli P , Clària J, Bataller R, Arroyo V, Forssmann WG, Rodés J. Hepatology. 1996 Dec;24(6):1428-32.

IF=11.190

51) Splenic Doppler impedance indeces: influence of dif ferent portal hemodynamic conditions. Bolognesi M., Sacerdoti D., Merkel C., Gerunda G., Maffei-Faccioli A., Angeli P ., Iemmolo RM., Bombonato GC., Gatta A. Hepatology 1996 ; 23 : 1035-1040. IF=11.190 52) Left ventricular diastolic function in liver cirr hosis. Finucci GF., Desideri A., Sacerdoti D., Bolognesi M., Merkel C., Angeli P., Gatta A. Scand. J. Gastroenerol. 1996 ; 31 : 279-284. IF=1.980 53) Nutritional and prognostic significance of insulin- like growth factor 1

in patients with liver cirrhosis. Caregaro L., Alberino F., Amodio P., Merkel C., Angeli P ., Plebani M,

Bolognesi M, Gatta A. Nutrition 1997 ; 13 : 185-190.

IF=2.329 54) Hemodynamic evaluation of the addition of isosorb ide-5-mononitrate

to nadolol in cirrhotic patients with insufficient response to the beta -blocker alone.

Merkel C., Sacerdoti D., Bolognesi M., Enzo E., Marin R., Bombonato G., Angeli P ., Gatta A.

Hepatology 1997 ; 26 : 34-39. IF=11.190

55) Eicosanoid excretion in hepatic cirrhosis. Predom inance of 20

-HETE. Sacerdoti D., Balazy M., Angeli P., Gatta A., McGiff JC. J. Clin. Invest. 1997 ; 100 : 1264-1270. .

IF=13.765 56) Infrahepatic terminolateral cavo-cavostomy as a rescue technique in

complicated “ modified “ piggyback liver transplant ation. Merenda R., Gerunda G., Neri D., Barbazza F., Di Marzio E., Bruttocao A.,Valmasoni M., Angeli P., Faccioli AM. J. Am. Coll. Surg. 1997 ; 185 : 576-579.

IF=4.450

57) Portal hypertensive gastropathy: reproducibility of a classification, prevalence of elementary lesions, sensitivity and s pecificity in the diagnosis of cirrhosis of the liver. A NIEC multice ntre study. New Italian Endoscopic Club. Carpinelli L., Primignani M., Preatoni P., Angeli P., Battaglia G., Beretta L., Bortoli A., Capria A., Cestari R., Cosentino F., Crotta S., Gerunda G., Lorenzini I., Maiolo P., Merighi A., Rossi A., Sangiovanni A., De Franchis R. Ital. J. Gastroenterol. Hepatol. 1997 ; 29 : 533-540. IF=1.594

58) Splenic impedence indices: a useful method to mon itor patients after

liver transplantation ? Bolognesi M., Sacerdoti D., Bombonato G., Angeli P., Gerunda G., Merenda R., Volpin R., Iemmolo R., Gatta A. Hepatology 1998 ; 27 : 674-678. IF=11.190

59) Nutritional and prognostic significance of serum hy pothyroxinemia

in hospitalized patients with liver cirrhosis. Caregaro L., Alberino F., Amodio P., Merkel C., Angeli P ., Plebani M,

Gatta A. J. Hepatol. 1998 ; 28 : 115-121.

I.F= 10.401

60) Q-T interval prolungation in liver cirrhosis. Rev ersibility after

orthotopic liver transplantation. Finucci G., Lunardi F., Sacerdoti D., Volpin R., Bortoluzzi A., Bombonato G., Angeli P., Gatta A. Jpn Heart J. 1998 ; 39 : 321-329. IF=1.080

61) Insulin-like growth factor 1 (IGF-1) in liver cir rhosis: a marker of

hepatocellular dysfunction ? Caregaro L., Alberino F., Angeli P ., Plebani M, Gatta A. JHepatol. 1998 ; 29 : 342 (Letter). I.F=10.401 62) Updating prognosis of cirrhosis by Cox’s regressi on model using

Child-P augh score and aminopyrine breath test as time-depen dent covariates.

Merkel C., Morbito A., Sacerdoti D., Bolognesi M., Angeli P., Gatta A. Ital. J. Gastroenterol. Hepatol. 1998 ; 30 : 276-282. IF=1.594 63) Effects of intravenous neuropeptide Y on insulin secretion and

insulin sensitivity in skeletal muscle in normal ra ts.

Vettor R., Pagano C., Granzotto M., Englaro P., Angeli P., Blum WF., Federspil G., Rohner-Jeanrenaud F., Jeanrenaud B.

Diabetologia 1998 ; 41 : 1361-1367. IF=6.880

64) Acute effects of the oral administration of midodri ne, an �-adrenergic

agonist, on renal hemodynamics and renal function i n cirrhotic patients with ascites. Angeli P. ,Volpin R., Piovan D., Bortoluzzi A., Craighero R., Bottaro S., Finucci GF., Casiglia E., Sticca A., De Toni R., Pavan L., Gatta A.

Hepatology 1998 ; 28 : 937-943. IF=11.190

65) Clinical practice guidelines for the management of cirrhotic patients

with ascites. Salerno F., Angeli P., Bernardi M., Laffi G., Riggio O., Salvagnini M. Ital. J. Gastroenterol. Hepatol. 1999 ; 31 : 626-634.

IF=1.594 66) Reversal of type 1 hepatorenal syndrome with the administration of

midodrine and octreotide. Angeli P, Volpin R, Gerunda G, Craighero R, Roner P, Merenda R,

Amodio P, Sticca A, Caregaro L, Maffei-Faccioli A, Gatta A. Hepatology 1999 ; 29 : 1690-1697.

IF=11.190

67) Effects of chronic treatment with nadolol plus is osorbide

mononitrate on liver metabolic activity in cirrhosi s. Merkel C., Sacerdoti D., Bolognesi M., Buonamico P., Sticca A., Amodio P., Angeli P., Micotti L., Gatta A. Eur. J. Gastroenterol. Hepatol. 1999 ; 11 : 1221-1225.

IF=2.150

68) Clinical features and survival of cirrhotic patien ts with subclinical

cognitive alterations by the number connection test and computerized psycometric tests.

Amodio P., Del Piccolo F., Marchetti PG., Angeli P., Iemmolo R., Caregaro L., Merkel C., Gerunda G., Gatta A. Hepatology 1999 ; 29 : 1662-1667. IF=11.190

69) Increased activity of guanosine 3’-5’-cyclic monop hosphate

phosphodiesterase in the renal tissue of cirrhotic rats with ascites. Angeli P., Jimenez W., Veggian R., Fasolato S., Volpin R., MacHenzie HS., Craighero R., Dalla Libera V., Sticca A., Arroyo V., Gatta A. Hepatology 2000; 31 : 304-310.

IF=11.190

70) Natural history of portal hypertensive gastropathy in patients with liver

cirrhosis. Primignani M., Carpinelli L., Preattoni P., Battaglia G., Carta A., Prada A., Cestari R., Angeli P., Gatta A., Rossi A., Spinzi GC., De Franchis R. Gastroenterology 2000 ; 119 : 181-187.

IF=13.926 71) Prognostic indicators of risk for first variceal bleeding in cirrhosis: a

multicenter study in 711 patients to validate and i mprove the North Italian Endoscopic Club (NIEC) Index. Merkel C., Zoli M., Siringo S., Van Buuren H., Magalotti D., Angeli P., Sacerdoti D., Bolondi L., Gatta A. Am. J. Gastroenterol. 2000 ; 95 : 2915-2920.

IF=9.213

72) Bacterial infections in patients with advanced cir rhosis: a multicentre prospective stydy. Borzio M., Salerno F., Piantoni L., Cazzaniga M., Angeli P., Bissoli F., Boccia S., Collaredo-Mels G., Corigliano P., Fornaciari G., Marenco G., Pistara R., Salvagnini M., Sangiovanni A., Dig. Liver Dis. 2001 ; 33 ; 41-48.

I.F= 2.889

73) Prevalence and prognostic value of quantified elec troencephalogram (EEG) alterations in cirrhotic patients. Amodio P., Del Piccolo F., Petteno E., Mapelli D., Angeli P., Iemmolo R., Muraca M., Musto C., Gerunda G., Rizzo C., Merkel C., Gatta A. J. Hepatol. 2001 ; 35 : 37-45.

I.F= 10.401

74) Cavoportal hemitransposition: a successful way to overcome the

problem of total portosplenomesenteric thrombosis i n liver transplantation. Gerunda G.E., Merenda R., Neri D., Angeli P., Barbazza F., Valmasoni M., Feltracco P., Zangrandi F., Gangemi A., Miotto D., Gagliesi A., Faccioli A.M. Liver Transpl. 2002 ; 8 : 72-75. I.F= 3.793

75) Change in portal flow after liver transplantation : effect on hepatic

arterial resistance indeces and role of spleen size . Bolognesi M., Sacerdoti D., Bombonato G.C., Merkel C., Sartori G., Merenda R., Nava V., Angeli P., Feltracco P., Gatta A. Hepatology 2002 ; 35 : 601-608.

I.F.= 11.190

76) Arteroportal fistulas between the accessory right hepatic,

gastroduodenal superior mesenteric arteries and por tal vein: a difficult technical problem to overcome in liver transplantat ion. Gerunda G.E., Merenda R., Neri D., Barbazza F., Angeli P., Sacerdoti D., Miotto D., Valmasoni M., Zangrandi F., Gangemi A., Faccioli A.M. Transplantation 2002 ; 73 : 417-419.

I.F.= 3.353

77) Comparison between two high-dose methylprednisol one

schedules in the treatment of acute hepatic cellula r rejection in liver transplant recipients: controlled clinical tr ial. Volpin R, Angeli P ., Galioto A., Fasolato S., Neri D., Barbazza F., Merenda R., Del Piccolo F., Strazzabosco M., Casagrande F., Feltracco P., Sticca A., Merkel C., Gerunda G., Gatta A. Liver Trasnspl. 2002 ; 8 : 527-534.

I.F= 3.793 78) Baised incorporation of ribonucleotides on the mit ochondrial strand

accounts for apparent strand-asymmetric DNA replica tion. Yang M.Y., Bowmaker M., Reyes A., Vergani L., Angeli P., Gringeri E., Jacobs H.T., Holt I. Cell 2002 ; 111: 495-505.

I.F= 33.116

79) Transduction of the liver with activated Akt norma lizes portal pressure

in cirrhotic rats. Morales-Ruiz M., Cejudo-Martin P., Fernandez-Varo G., Tugues S., Ros J., Angeli P. , Rivera F., Arroyo V., Rodes J., Sessa W.C., Jimenez W. Gastroenterology ; 2003 : 125: 522-531.

I.F= 13.926

80) The management of ascites in cirrhosis: report on the consensus conference of the International Ascites. Moore K.P., Wong F., Gines P., Bernardi M., Ochs A., Salerno F., Angeli P., Porayko M., Moreau R., Garcia-Tsao G, Jimenez W., Planas R., Arroyo V. Hepatology 2003 ; 38: 522-531.

I.F.= 11.190

81) Portal hypertension and portal hypertensive gastro pathy in patients

with cirrhosis: an haemodynamic study. Merkel C., Schipilliti M., Bigin R., Bellini B., Angeli P ., Bolognesi M., Vescovi F., Gatta A.

Dig. Liver Dis. 2003 ; 35: 269-274. I.F= 2.889

82) A placebo-controlled clinical trial of nadolol in the prophylaxis of

growth of small esophageal varices in cirrhosis. Merkel C., Marin R., Angeli P., Zanella P., Felder M., Bernardinello E., Cavallarin G., Bolognesi M., Donada C., Bellini B., Torboli P., Gatta A. Gastroenterology 2004 ; 127: 476-484.

I.F = 13.926

83) The role of nitric oxide in the pathogenesis of s ystemic and

splanchnic vasodilation in cirrhotic rats before an d after the onset of ascites. Angeli P., Fernandez-Varo G, Dalla Libera V, Fasolato S., Galioto A, Arroyo V, Sticca A., Guarda S., Gatta A., Jimenez W. Liver Int. 2005 ; 25: 429-437.

I.F =4.447 84) Review article: prognosis of hepatorenal syndrome , has it changed with

current practice. Angeli P. Aliment. Pharmacol. Ther. 2004 ; 3 (Suppl. 3) : 44-48.

I.F.= 5.478

85) Acute liver rejection:accuracy and predictive valu es of doppler US

measurements: initial experience. Bolognesi M., Sacerdoti D., Mescoli C., Nava V., Bombonato G., Merkel C., Merenda R., Angeli P., Rugge M., Gatta A. Radiology.. 235 ; 37: 651-658.

I.F = 6.214

86) Comparison between nifedipine and carvedilol in the treatment of de

novo arterial hypertension after liver transplantat ion: preliminary results of a controlled clinical trial. Galioto A, Angeli P., Guarda S., Burra P., Zanus G., Fasolato S., FagiuoliS., Sticca A., Semplicini A., Sartori M., Carraro A., Boccagni P., Cillo C., Gatta A. Trasnplant Proc.. 2005 ; 37: 1245-1247.

I.F = 0.984

87) Haeme oxygenase mediates hyporeactivity to phenyle phrine in the

mesenteric vessels of cirrhotic rats with ascites.

Bolognesi M., Sacerdoti D., Di Pascoli M., Angeli P., Quarta S., Sticca A., Pontisso P., Merkel C., Gatta A Gut.. 2005 ; 11: 1630-1637.

I.F= 13.319

88) P300 latency for the diagnosis of minimal hepatic e ncephalopathy: evidence that spectral EEG analysis and psychome tric tests are enough. Amodio P, Valenti P, Del Piccolo F, Pellegrini A, Schiff S, Angeli P , Poci C, Mapelli D, Iannizzi P, Gatta A. Dig Liver Dis. 2005 Nov;37(11):861-8. Epub 2005 Sep 23. I.F=2.889 89) The effectiveness of human albumin in liver failure . Angeli P , Gatta A. Minerva Anestesiol. 2005 Dec;71(12 Suppl 1):17-26. Review. Italian. No abstract available. I.F=2.272 90) Switch therapy with ciprofloxacin vs intravenous c eftazidime in the

treatment of spontaneous bacterial peritonitis in p atients with cirrhosis; similar efficacy at lower cost. Angeli P., Guarda S., Fasolato S, Miola E., Craighero R., Del Piccolo F., Antona C., Brollo L., Franchin M., Cillo U, Merkel C., Gatta A. Alimentary Pharmacol. Ther 2006 ; 23: 75-84.

I.F. = 5.478

91) Hyponatremia in cirrhosis: results of a patient po pulation survey.

Angeli P., Wong F., Watson H., Gines P., CAPPS Investigators. Hepatology 2006 ; 44: 1535-1542. I.F. =

11.190 92) Renal failure and bacterial infections in patients with cirrhosis:

epidemiology and clinical feature. Fasolato S., Angeli P ., Dallagnese L., Maresio G., Zola E., Elena M., Salinas F., Dona S., Fagiuoli S., Sticca A., Zanus G., Cillo U., Frasson I, Destro C., Gatta A. Hepatology 2007 ; 45 : 223-229

I.F. = 11.190

93) Carbon monoxide-mediated activation of a large-co nductance calcium-

activated potassium channels contrinutes to mesente ric vasodilation in cirrhotic rats. Bolognesi M., Sacerdoti D., Piva A., Di Pascoli M., Zampieri F., Quarta S., Motterlini R.,Angeli P ., Merkel C., Gatta A. J. Pharmacol. Exp. Ther. 2007 ; 321 : 187-194.

I.F. = 3.855

94) Intention to treat analysis of liver transplantat ion in selected,

aggressively treated HCC patients exceeding the Mil an criteria. Cillo U., Vitale A., Grigoletto F., D’Amico F., Valmasoni M., Brolese A., Zanus G,. Sersen N., Carraro A., Burra P., Farinati F., Angeli P., D’Amico DF. Am. J. Transplant. 2007 ; 7 : 972-981.

I.F = 6.190

95) Alcohol- and substance-dependent subjects: the cor related factors in

qualifying for liver transplantation. Galimberti L., Forza G., Angeli P., Vitale A., Cillo U., Gatta A., D’Amico D. Transplant. Proc. 2007 ; 39 : 1861-1863.

I.F = 0.984

96) Neurological complications after liver transplanta tion.

Amodio P., Biancardi A., Montagnose S., Angeli P., Iannizzi P., Cillo U., D’Amico D., Gatta A. Dig. Liver Dis. 2007 ; 39 : 740-747.

I.F= 2.889 97) Nifedipine versus carvedilol in the treatment of de novo arterial hypertension after liver transplantation; result s of a controlled clinical trial. Galioto A., Semplicioni A., Zanus G., Fasolato S., Sticca A., Boccagni P., Frigo A.C., Cillo U. Angeli P. Liver Transpl. 2008 ; 14 : 1020-1028.

I.F = 3.793

98) Pathogenesis and management of hepatorenal sindro me. Angeli P. Merkel C.

J. Hepatol. 2008 ; 48 (suppl. 1) S93-S103. I.F=

10.401 99) An abnormal gene expression of betaadrenergic sys tem contributes to the pathogenesis of cardiomiopathy in cirrhotic rats. Ceolotto G., Papparella I., Sticca A., Cavalli M., Cargnelli G., Semplicini A., Gatta A., Angeli P.

Hepatology 2008 48 ; 1913-1923. I.F =

11.190 100) Effects of satavaptan, a selective vasopressin (V 2) receptor antagonist, on ascites and serum sodium in cirrh osis with hyponatremia: a randomized trial. Gines P., Wong F., Watson H., Milutinovic S., Del Arbor L.R., Olteanu D. HypoCAT Study Investgators (among them P. Angeli). Hepatology 2008 48 ; 204-213.

I.F = 11.190

101) Detection of minimal hepatic encephalopathy; norma lization and optimization of the Psycometric Hepatic Encephal opathy Score. A neuropsycological and quantified EEG study. Amodio P., Campagna F., Olianas S., Iannizzi P., Mapelli D., Penzo M., Angeli P., Gatta A. J. Hepatol. 2008 49 ; 346-353. I.F= 10.401

102) Combined versus sequential diuretic treatment of a scites in nonazotemic patients with cirrhosis: results of an open randomized clinical trial. Angeli P , Fasolato S, Mazza E, Okolicsanyi L, Maresio G, Velo E, Galioto A, Salinas F, D'Aquino M, Sticca A, Gatta A. Gut. 2010 ; 59 : 98-104.

I.F= 13.319

103) Electroencephalographic analysis for the assessmen t of hepatic encephalopathy: comparison of non-parametric and pa rametric spectral estimation techniques. Amodio P, Orsato R, Marchetti P, Schiff S, Poci C, Angeli P , Gatta A, Sparacino G, Toffolo GM. Neurophysiol Clin. 2009 ; 39 :107-115.

I.F= 1.463

104) Prognostic evaluation of the donor risk index amon g a prospective cohort of Italian patients undergoing liver transpl antation.

Vitale A, D'Amico F, Gringeri E, Valmasoni M, Pauletto A, Bonsignore P, Bassi D, D'Amico FE, Polacco M, Burra P, Russo F, Angeli P , Poci C, Feltracco P, Romano A, Cillo U. Transplant Proc. 2009 May;41(4):1096-1098

I.F= 0.984

105) Prospective validation of a new priority allocatio n model for liver transplant candidates: an interim analysis. Vitale A, Saracino E, D'Amico FE, Grigoletto F, Burra P, Angeli P , Boccagni P, Brolese A, Zanus G, Neri D, Gringeri E, D'Amico F, Valmasoni M, Carraro A, Gambato M, Feltracco P, Romano A, Buggio M, D'Amico DF, Cillo U. Transplant Proc. 2009 May;41(4):1092-5

I.F= 0.984

106) What is behind the presence of anti-neutrophil cyt oplasmatic antibodies in chronic liver disease? De Riva V, Celadin M, Pittoni M, Plebani M, Angeli P. Liver Int. 2009 Jul;29(6):865-70. Epub 2009 May 6.

I.F= 4.447

107) Post-transplant lymphoproliferative disorders in l iver transplanted

patients: a single-centre experience. Marino D, Burra P, Boccagni P, Calabrese F, Canova F, Trentin C, Boso C, Soldà C, Angeli P, Aversa SM.

Anticancer Res. 2010 ; 30 : 2383-2391 I.F=

1.872

108) Effects of a selective vasopressin V2 receptor an tagonist, satavaptan,

on ascites recurrence after paracentesis in patient s with cirrhosis. Wong F, Gines P, Watson H, Horsmans Y, Angeli P, Gow P, Minini P, Bernardi M. J. Hepatol. 2010 ; 53 : 283-290. I.F=

10.401 109) EASL clinical practice guidelines on the management of ascites,

spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. European Association for the Study of the Liver, Ginès P, Angeli P, Lenz K, Møller S, Moore K, Moreau R, Merkel C, Ring-Larsen H, Bernardi M, Garcia-Tsao G, Hayes P. J. Hepatol. 2010 ; 53 : 347-417.

I.F= 10.401

110) Prediction of oesophageal varices in hepatic cir rhosis by simple serum

non-invasive markers: Results of a multicenter, lar ge-scale study. Sebastiani G, Tempesta D, Fattovich G, Castera L, Halfon P, Bourliere M, Noventa F, Angeli P, Saggioro A, Alberti A. J. Hepatol. 2010 ; 53 : 630-638

I.F= 10.401

111) Refractory ascites: pathogenesis, definition an d therapy of a severe

complication in patients with cirrhosis. Salerno F, Guevara M, Bernardi M, Moreau R, Wong F, Angeli P, Garcia-Tsao G, Lee SS. Liver Int. 2010 ; 30 : 937-947 I.F=

4.447

112) Response to therapy as a criterion for awarding pr iority to patients with hepatocellular carcinoma awaiting liver transplanta tion. Vitale A, D'Amico F, Frigo AC, Grigoletto F, Brolese A, Zanus G, Neri D, Carraro A, D'Amico FE, Burra P, Russo F, Angeli P, Cillo U. Ann. Surg. Onc. 2010 ; 17 : 2290-2302. I.F=

3.943

113) The survival benefit of liver transplantation in he patocellular carcinoma patients. Cillo U, Vitale A, Volk ML, Frigo AC, Grigoletto F, Brolese A, Zanus G, D'Amico F, Farinati F, Burra P, Russo F, Angeli P, D'Amico DF. Dig. Liver Dis. 2010 ; 42 : 642-649.

I.F.=

2.889

114) Estimation of the harm to the waiting list as a cru cial factor in the selection of patients with hepatocellular carcinoma for liver transplantation. Vitale A, Volk ML, Gambato M, Zanus G, D'Amico F, Carraro A, Pauletto A, Bonsignore P, Scopelliti M, Polacco M, Russo F, Senzolo M, Burra P, Romano A, Angeli P, Cillo U.

Transpl. Proc. 2010 ; 42 : 1194-1196. I.F= 0.984

115) Clinical trial: short-term effects of combination o f satavaptan, a

selective vasopressin V2 receptor antagonist, and d iuretics on ascites in patients with cirrhosis without hyponatraemia--a randomized, double-blind, placebo-controlled study . Ginès P, Wong F, Watson H, Terg R, Bruha R, Zarski JP, Dudley F; NormoCAT Study Investigators. Aliment. Pharmacol. Ther. 2010 ; 31 : 834-845.

I.F= 5.478

116) Use of sorafenib in patients with hepatocellular ca rcinoma before liver

transplantation: a cost-benefit analysis while awai ting data on sorafenib safety. Vitale A, Volk ML, Pastorelli D, Lonardi S, Farinati F, Burra P, Angeli P, Cillo U. Hepatology 2010 ; 51 : 165-173.

I.F = 11.190

117) Improving the inhibitory control task to detect m inimal hepatic

encephalopathy. Amodio P, Ridola L, Schiff S, Montagnese S, Pasquale C, Nardelli S, Pentassuglio I, Trezza M, Marzano C, Flaiban C, Angeli P, Cona G, Bisiacchi P, Gatta A, Riggio O. Gastroenterology 2010 ; 139 : 510-518.

I.F=13.926

118) Different biochemical correlates for different ne uropsychiatric abnormalities in patients with cirrhosis Montagnese S, Biancardi A, Sciff S, Carraro P, Carlà V, Mannaioni G, Moroni F, Tono N, Angeli P , Amodio P. Hepatology 2011 ; 53 : 558-566

I.F=11.190

119) Working party proposal for a revised classificati on system of renal dysfunction in patients with cirrhosis Wong F, Nadim MK, Kellum JA, Salerno F, Bellomo R, Gerbes A, Angeli P, Moreau R, Jalan R, Ronco C, Genyk Y, Arroyo V. Gut 2011 [Epub ahead of print] I.F=

13.319

120) Continuous recurrence of type 1 hepatorenal syndr ome and long-term treatment with terlipressin and albumin. A new exce ption to MELD score in the allocation system to liver transplanta tion? Piano S, Morando F, Fasolato S, Cavallin M, Boscato N, Boccagni P, Zanus G, Cillo U, Gatta A, Angeli P. J. Hepatol. 2011 [Epub ahead of print]

I.F= 10.401

121) The liver: another organ involved in Muir Torre s yndrome?

Morando F, Alaibac M, Romano A, Cavallin M, Piano S, Pizzi M, Mescoli C, Pilati P, Gatta A, Angeli P. Fam Cancer 2011 [Epub ahead of print]

I.F=1.618 122) β-blockers and refractory ascites in cirrhosis: the message of a team of

true scientists Angeli P. J. Hepatol 2011 [Epub ahead of print]

I.F= 10.401

123) A novel approach to severe acute pancreatitis in s equential liver-kidney

transplantation: the first report on the application of VAC therapy Zanus G, Boetto R, D’Amico F, Gringeri E, Vitale A, Carraro A, Bassi D, Scopelliti M, Bonsignore P, Burra P, Angeli P, Feltracco P, Cillo U. Transplant. Int. 2011 ; 24 : e23-e27.

I.F.=3.120

124) Microwave thermal ablation for hepatocarcinoma: si x liver transplantation cases Zanus G, Boetto R, Grigeri E, Vitale A, D’Amico F, Carraro A, Bassi D, Bonsignore P, Noaro G, Mescoli C, Rugge M, Burra P, Angeli P, Senzolo M, Burra P, Feltracco P, Cillo U. Transplant.Proc. 2011 ; 43 : 1091-1094. I.F.=

0.984

125) Donor-model for end-stage liver disease and donor- recipient matching in liver transplantation Vitale A, Ramirez-Morales R, Scopelliti M, Zanus G, Neri D, D’Amico F,

Russo F, Burra P, Angeli P, Cillo U. Transplant. Proc. 2011 ; 43 : 974-976.

I.F.= 0.984

126) Diagnosis, treatment survival of patients with h epatorenal syndrome: a survey on daily medical practice

Salerno F, cazzaniga M, Merli M, Spinzi G, Saibeni S, Salmi A, Fagiuoli S, Spadaccini A, Trotta E, Laffi G, Koch M, Riggio O, Boccia S, Felder M, Balzani S, Bruno S, Angeli P.

J Hepatol. 2011 Dec;55(6):1241-8. doi: 10.1016/j.jhep.2011.03.012. Epub 2011 Apr 13.

1I.F= 10.401

127) Barcelona Clinic Liver Cancer staging and transpla nt survival benefit for patients with hepatocellular carcinoma: a mulc entre, cohort study

Vitale A, Morales RR, Zanus G, Farinati F, Burra P, Angeli P , Frigo AC, Del Poggio P, Rapaccini G, Di Nolfo MA, Benvegnù L, Zoli M, Borzio F, Giannini EG, Caturelli E, Chiaramonte M, Trevisani F, Cillo U. On behalf of the Italian Liver Cancer Group. Lancet Oncology 2011 ; 12 : 654-662. I.F= 24.725

128) Increased myoendothelial gap junctions mediate the enhanced response to epoxyeicosatrienoic acid and acetylch oline in mesenteric arterial vessels of cirrhotic rats. Bolognesi M, Zampieri F, Di Pascoli M, Verardo A, Turato C, Calabrese F, Lunardi F, Pontisso P, Angeli P, Merkel C, Gatta A, Sacerdoti D. Liver Int. 2011 ; 31 : 881-890.

I.F= 4.447 129) Diagnosis, treatment and survival of patients wit h hepatorenal syndrome: A survey on daily medical practice. Salerno F, Cazzaniga M, Merli M, Spinzi G, Saibeni S, Salmi A, Fagiuoli S, Spadaccini A, Trotta E, Laffi G, Koch M, Riggio O, Boccia S, Felder M, Balzani S, Bruno S, Angeli P.

J Hepatol. 2011 Apr 13. [Epub ahead of print] I.F= 10.401

130) Hepatorenal syndrome. Angeli P, Morando F, Cavallin M, Piano S. Contrib. Nephrol. 2011 ; 174 : 46-55.

I.F= 1.487

131) Monoclonal gammopathy after liver transplantation: a risk factor for long- term medical complications other than maligna ncies.

Galioto A, Morando F, Rosi S, Schipilliti M, Fasolato S, Magrin M, Frigo AC, Adami F, Cavallin M, Zanus G, Plebani M, Romano A, Sticca A, Cillo U, Gatta A, Angeli P. Transpl Int. 2012 Jan;25(1):25-33

I.F= 3.120

132) What type of probiotic was used? Montagnese S, Amodio P, Angeli P . Eur J Gastroenterol Hepatol. 2012 Apr;24(4):471-2 I.F= 1.757 133) Immune thrombocytopenic purpura and Kaposi's sarcom a in a liver transplant recipient.

Piano S, Gatta A, Angeli P. Transpl Int. 2012 Apr;25(4):e50-2

I.F= 3.120

134) Mutation analysis of the ATP7B gene in a new group of Wilson's disease patients: contribution to diagnosis.

Lepori MB, Zappu A, Incollu S, Dessì V, Mameli E, Demelia L, Nurchi AM, Gheorghe L, Maggiore G, Sciveres M, Leuzzi V, Indolfi G, Bonafé L, Casali C, Angeli P , Barone P, Cao A, Loudianos G. Mol Cell Probes. 2012 Aug;26(4):147-50

I.F= 1.859 135) Current limits and future challenges in the managem ent of renal dysfunction in patients with cirrhosis: report fro m the International Club of Ascites.

Angeli P , Sanyal A, Moller S, Alessandria C, Gadano A, Kim R, Sarin SK, Bernardi M; International Club of Ascites. Liver Int. 2013 Jan;33(1):16-23

I.F= 4.447

136) Spontaneous bacterial peritonitis due to carbapenem ase-producing

Klebsiella pneumoniae: the last therapeutic challe nge. Piano S, Romano A, Rosi S, Gatta A, Angeli P . Eur J Gastroenterol Hepatol. 2012 Oct;24(10):1234-7

I.F= 2.152

137) Hepatorenal syndrome, MELD score and liver transpla ntation: an evolving issue with relevant implications for clin ical practice.

Angeli P , Gines P. J Hepatol. 2012 Nov;57(5):1135-40.

I.F= 10.401

138) A patients' and caregivers' perspective on hepatic encephalopathy.

Montagnese S, Amato E, Schiff S, Facchini S, Angeli P , Gatta A, Amodio P. Metab Brain Dis. 2012 Dec;27(4):567-72.

I.F= 2.398

139) Positive cardiac inotropic effect of albumin infusi on in rodents with cirrhosis and ascites: molecular mechanisms.

Bortoluzzi A, Ceolotto G, Gola E, Sticca A, Bova S, Morando F, Piano S, Fasolato S, Rosi S, Gatta A, Angeli P . Hepatology. 2013 Jan;57(1):266-76

I.F=11.190

140) Severe acute hepatitis B in a treatment-naïve patie nt with antiviral drug resistant mutations in the polymerase gene.

Morando F, Rosi S, Fasolato S, Cavallin M, Gola E, Gatta A, Angeli P . J Med Virol. 2013 Feb;85(2):210-3

I.F= 2.217

141) Severe Liver Cirrhosis Markedly Reduc es AhR-Mediated Induction of Cytochrome P450 in Rats by Decreasing the Transc ription of Target Genes Maura Floreani, Sara De Martin, Daniela Gabbia, Massimo Barbierato, Alberto Nassi, Claudia Mescoli, Rocco Orlando, Sergio Bova, Paolo Angeli, Elisabetta Gola, Antonietta Sticca, Pietro Palatini PLoS One. 2013; 8(4): e61983. Published online 2013 April 23. doi: 10.1371/journal.pone.0061983

I.F=3.534

142) Excessive daytime sleepiness and hepatic encephalop athy: it is worth asking. De Rui M, Schiff S, Aprile D, Angeli P , Bombonato G, Bolognesi M, Sacerdoti D, Gatta A, Merkel C, Amodio P, Montagnese S.

Metab Brain Dis. 2012 Nov 18. I.F=

2.398 143) Model for end-stage liver disease-sodium and surviv al benefit in liver transplantation.

Vitale A, Bertacco A, Gambato M, D'Amico F, Morales RR, Frigo AC, Zanus G, Burra P, Angeli P , Cillo U. Transpl Int. 2013 Feb;26(2):138-44

I.F=3.120

144) Serum free light chain reference values: A critical approach.

Altinier S, Seguso M, Zaninotto M, Varagnolo M, Adami F, Angeli P , Plebani M. Clin Biochem. 2013 Feb 4. doi:pii: [Epub ahead of print]

I.F= 2.229

145) Acute-on-chronic liver failure is a distinct syndrome that develops in patients with

acute decompensation of cirrho sis. Moreau R, Jalan R, Gines P, Pavesi M, Angeli P , Cordoba J, Durand F, Gustot T,Saliba F, Domenicali M, Gerbes A, Wendon J, Alessandria C, Laleman W, Zeuzem S, Trebicka J, Bernardi M, Arroyo V; CANONIC Study Investigators of the EASL–CLIF Consortium. Gastroenterology. 2013 Jun;144(7):1426-37, 1437.e1-9. doi: 10.1053/j.gastro.2013.02.042. Epub 2013 Mar 6.

I.F=13.926

146) How to improve care in outpatients with cirrhosis a nd ascites: a new model of care coordination by consultant hepat ologists. Morando F, Maresio G, Piano S, Fasolato S, Cavallin M, Romano A, Rosi S, Gola E,FrigoAC,Stanco M, Destro C, Rupolo G, Mantoan D, Gatta A, Angeli P . J Hepatol. 2013 Aug;59(2):257-64. doi: 10.1016/j.jhep.2013.03.01 Epub 2013 Mar 21.

I.F=10.401

147) Evaluation of the Acute Kidney Injury Network crite ria in hospitalized patients with cirrhosis and ascites. Piano S, Rosi S, Maresio G, Fasolato S, Cavallin M, Romano A, Morando F, Gola E, Frigo AC, Gatta A, Angeli P . J Hepatol. 2013 Sep;59(3):482-9. doi: 10.1016/j.jhep.2013.03.039. Epub 2013 May 7.

I .F=10.401

I

148) Characteristics, risk factors, and mortality of cir rhotic patients hospitalized for hepatic encephalopathy with and without acu te-on-chronic liver failure (ACLF). Cordoba J, Ventura-Cots M, Simón-Talero M, Amorós À, Pavesi M, Vilstrup H, Angeli P , Domenicali M, Ginés P, Bernardi M, Arroyo V; CANONIC Study Investigators of EASL-CLIF Consortium. J Hepatol. 2014 Feb;60(2):275-81. doi: 10.1016/j.jhep.2013.10.004. Epub 2013 Oct 12.

I.F=10.401 149) A method for establishing allocation equity among p atients with and without hepatocellular carcinoma on a common liver transplant waiting list. Vitale A, Volk ML, De Feo TM, Burra P, Frigo AC, Ramirez Morales R, De Carlis L, Belli L, Colledan M, Fagiuoli S, Rossi G, Andorno E, Baccarani U, Regalia

E, Vivarelli M, Donataccio M, Cillo U; Liver Transplantation North Italy Transplant program (NITp) working group. J Hepatol. 2014 Feb;60(2):290-7. doi: 10.1016/j.jhep.2013.10.010. Epub 2013 Oct 23. Erratum in: J Hepatol. 2014 Jun;60(6):1336. Multipile investigator names added.

I.F=10.401

150) Reply to: "Coordinated care models in cirrhosis; th e need for further randomized controlled trials" . Morando F, Piano S, Angeli P . J Hepatol. 2014 Feb;60(2):466-7. doi: 10.1016/j.jhep.2013.10.022. Epub 2013 Nov 1. No abstract available.

I.F=10.401

151) "To close the stable door before the horse has bol ted". Piano S, Morando F, Angeli P . J Hepatol. 2014 Mar;60(3):680-1. doi: 10.1016/j.jhep.2013.11.026. Epub 2013 Dec 1. No abstract available.

I.F=10.401

152) Adherence to a moderate sodium restriction diet in outpatients with cirrhosis and ascites: a real-life cross-sect ional study. Morando F, Rosi S, Gola E, Nardi M, Piano S, Fasolato S, Stanco M, Cavallin M, Romano A, Sticca A, Caregaro L, Gatta A, Angeli P . Liver Int. 2014 May 8. doi: 10.1111/liv.12583. [Epub ahead of print]

I.F=4.447

153) Bacterial infections in cirrhosis: a position state ment based on the EASL Special Conference 2013. Jalan R, Fernandez J, Wiest R, Schnabl B, Moreau R, Angeli P , Stadlbauer V, Gustot T, Bernardi M, Canton R, Albillos A, Lammert F, Wilmer A, Mookerjee R, Vila J, Garcia-Martinez R, Wendon J, Such J, Cordoba J, Sanyal A, Garcia-Tsao G, Arroyo V, Burroughs A, Ginès P.

J Hepatol. 2014 Jun;60(6):1310-24. doi: 10.1016/j.jhep.2014.01.024. Epub 2014 Feb 12. I.F=10.401

154) Life-threatening coagulopathy and hypofibrinogena emia induced by tigecycline in a patient with advanced liver cir rhosis. Rossitto G, Piano S, Rosi S, Simioni P, Angeli P . Eur J Gastroenterol Hepatol. 2014 Jun;26(6):681-4. doi: 10.1097/MEG.0000000000000087. I.F=2.152 155) Early markers of neural dysfunction and compensatio n: a model from minimal hepatic encephalopathy. Cona G, Montagnese S, Bisiacchi PS, Gatta A, Cillo U, Angeli P , Amodio P, Schiff S. Clin Neurophysiol. 2014 Jun;125(6):1138-44. doi: 10.1016/j.clinph.2013.10.048. Epub 2013 Nov 19. I.F=2.979 156) Assessment of alcohol consumption in liver transpla nt candidates and recipients: the best combination of the tools ava ilable. Piano S, Marchioro L, Gola E, Rosi S, Morando F, Cavallin M, Sticca A, Fasolato S, Forza G, Chiara Frigo A, Plebani M, Zanus G, Cillo U, Gatta A, Angeli P . Liver Transpl. 2014 Jul;20(7):815-22. doi: 10.1002/lt.23881. Epub 2014 May 26. I.F=3.793 157) Confounders in the detection of minimal hepatic enc ephalopathy: a neuropsychological and quantified EEG study. Campagna F, Montagnese S, Schiff S, Ruzzoli M, Biancardi A, Iannizzi P, Pujatti PL, Angeli P , Gatta A, Merkel C, Leandro G, Mapelli D, Amodio P. Liver Int. 2014 Jul 9. doi: 10.1111/liv.12635. [Epub ahead of print] I.F=4.447 158) Cognitive impairment and electroencephalographic al terations before and after liver transplantation: what is reversi ble? Campagna F, Montagnese S, Schiff S, Biancardi A, Mapelli D, Angeli P , Poci C, Cillo U, Merkel C, Gatta A, Amodio P. Liver Transpl. 2014 Aug;20(8):977-86. doi: 10.1002/lt.23909. I.F=3.793

159) Survival benefit of transplantation for recurrence of hepatocellular carcinoma after liver resection. Tuci F, Vitale A, D'Amico F, Gringeri E, Neri D, Zanus G, Bassi D, Polacco M, Boetto R, Lodo E, Germani G, Burra P, Angeli P , Cillo U. Transplant Proc. 2014 Sep;46(7):2287-9. doi: 10.1016/j.transproceed.2014.07.031. I.F=0.984

160) Acute kidney injury and acute-on-chronic liver fail ure classifications in prognosis assessment of patients with acute decom pensation of cirrhosis. Angeli P, Rodríguez E, Piano S, Ariza X, Morando F, Solà E, Romano A, García E, Pavesi M, Risso A, Gerbes A, Willars C, Bernardi M, Arroyo V, Ginès P; for the CANONIC Study Investigators of the EASL-CLIF Consortium. Gut. 2014 Oct 13. pii: gutjnl-2014-307526. doi: 10.1136/gutjnl-2014-307526. [Epub ahead of print] I.F=13.319

161) Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. Jalan R, Saliba F, Pavesi M, Amoros A, Moreau R, Ginès P, Levesque E, Durand F, Angeli P , Caraceni P, Hopf C, Alessandria C, Rodriguez E, Solis-Muñoz P, Laleman W, Trebicka J, Zeuzem S, Gustot T, Mookerjee R, Elkrief L, Soriano G, Cordoba J, Morando F, Gerbes A, Agarwal B, Samuel D, Bernardi M, Arroyo V; CANONIC study investigators of the EASL-CLIF Consortium. J Hepatol. 2014 Nov;61(5):1038-47. doi: 10.1016/j.jhep.2014.06.012. Epub 2014 Jun 17 I.F=10.401

162) Covert hepatic encephalopathy: agreement and predic tive validity of different indices. Montagnese S, Balistreri E, Schiff S, De Rui M, Angeli P , Zanus G, Cillo U, Bombonato G, Bolognesi M, Sacerdoti D, Gatta A, Merkel C, Amodio P. World J Gastroenterol. 2014 Nov 14;20(42):15756-62. doi: 10.3748/wjg.v20.i42.15756. I.F=2.433

163) The CLIF Consortium Acute Decompensation score (CLI F-C ADs) for prognosis of hospitalised cirrhotic patients with out acute-on-chronic liver failure . Jalan R, Pavesi M, Saliba F, Amorós A, Fernandez J, Holland-Fischer P, Sawhney R, Mookerjee R, Caraceni P, Moreau R, Gines P, Durand F, Angeli P , Alessandria C, Laleman W, Trebicka J, Samuel D, Zeuzem S, Gustot T,

Gerbes AL, Wendon J, Bernardi M, Arroyo V; CANONIC Study Investigators; EASL-CLIF Consortium. J Hepatol. 2014 Nov 22. pii: S0168-8278(14)00856-3. doi: 10.1016/j.jhep.2014.11.012. [Epub ahead of print]

I.F=10.401 164) Improving quality of health care for patients wit h cirrhosis. Kanwal F, Volk M, Singal A, Angeli P , Talwalkar J. Gastroenterology. 2014 Dec;147(6):1204-7. doi: 10.1053/j.gastro.2014.10.029. Epub 2014 Oct 25. No abstract available I.F=13.926 165) Reply to: "A cut-off serum creatinine value of 1.5 mg/dl for AKI - To be or not tobe" Piano S, Tonon M, Cavallin M, Morando F, Romano A, Gola E, Fasolato S, Angeli P . J Hepatol. 2014 Dec 5. pii: S0168-8278(14)00890-3. doi: 10.1016/j.jhep.2014.12.001. [Epub ahead of print] No abstract available. I.F=10.401 166) Prognostic Benefit of the Addition of a Quantitati ve Index of Hepatic Encephalopathy to the MELD score: the MELD-EEG. Montagnese S, De Rui M, Schiff S, Ceranto E, Valenti P, Angeli P , Cillo U, Zanus G, Gatta A, Amodio P, Merkel C. Liver Int. 2015 Jan;35(1):58-64. doi: 10.1111/liv.12490. Epub 2014 Mar 12. I.F=4.447